Clinical Trial Update: Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine, docetaxel, and capecitabine for carcinoma of unknown primary has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• Docetaxel (Taxotere) (docetaxel)
• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Carcinoma of Unknown Primary | Phase 2 | Status: WITHDRAWN